Résztvevőt keres3. fázis
A study to evaluate the immune response and safety of a vaccine against influenza in adults 18-64 years of age
A legfontosabb adatok
- Ki végzi
- GlaxoSmithKline Biologicals
- Hol
- Belgium és Németország8 helyszín, 2 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 1500 fő, tervezett
- Kezdés
- 2026. okt. 16.
- Várható befejezés
- 2027. júl. 9.
- A vizsgálat típusa
- Beavatkozással járó
- A regiszteradat frissítve
- 2026. október 6.
Ki vehet részt
- Életkor
- 18 év – 64 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Részt vehetnek
A regiszter feltételei, szó szerint
Mind a 12 feltétel megnézéseKevesebb
Ki vehet részt
- Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the eDiary, return for follow-up visits, attendance to study contacts, and ability to access and utilize a phone or other electronic communications) independently or with the assistance of a caregiver
- Written or witnessed (physically or digitally) informed consent obtained from the participant/LAR(s) of the participant prior to performance of any study-specific procedure
- Healthy participants or medically stable patients as established by medical history and clinical examination. Participants with chronic medical conditions with or without specific treatment (e.g., chronic metabolic, cardiac, pulmonary, renal, hepatic, neurologic, and hematologic diseases) are allowed to participate in this study if considered by the investigator as medically stable. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during 3 months before enrollment
- A male or female participant between and including 18 to 64 YOA at the time of the study intervention administration
- For further inclusion criteria, kindly refer to the protocol (Section 5.1)
Ki nem vehet részt
- Administration of an influenza vaccine in the period starting 180 days before the study intervention administration or planned administration prior to Visit 2 during the study
- History of test confirmed influenza infection within 180 days prior to study intervention administration
- Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or planned use of long-acting immune modifying treatments at any time up to the end of the study. • Up to 90 days prior to the study intervention administration: o For systemic corticosteroids: prednisone equivalent ≥20 mg/day for >14 days. Inhaled, intra articular/intra-bursal, and topical steroids are allowed. o Long-acting immune modifying drugs including, among others, immunotherapy (e.g., TNF inhibitors), monoclonal antibodies, antitumoral medication
- History of myocarditis or pericarditis considered causally associated with the administration of an mRNA vaccine
- Acute or unstable chronic conditions [clinically significant pulmonary, cardiovascular, hepatic, metabolic/endocrine disorders, renal functional abnormality, or psychiatric conditions], as determined by medical history and clinical examination
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required). HIV infected individuals may be enrolled if they have been stable on antiretroviral therapy for the past 6 consecutive months, i.e., their treatment has not been modified, their CD4 cell count is ≥200/mm³ and their viral load has been undetectable (i.e., HIV-RNA < 50 copies/mL)
- For further exclusion criteria, kindly refer to the protocol (Section 5.2)
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 64 év között vagy?
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
2 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
To demonstrate the non-inferiority of the investigational study intervention in adults 18-64 YOA as compared to adults aged 65 YOA and older in study FLU SV MRNA-006 in terms of humoral immune response to the HA and NA antigens. To demonstrate the non-inferiority of the investigational study intervention as compared to Flu D-TIV in adults 18-64 YOA in terms of humoral immune response to the HA antigens. To evaluate the safety and reactogenicity of the study interventions.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- A phase 3 randomized, observer-blind, controlled study to evaluate the immunogenicity, reactogenicity and safety of an mRNA-based seasonal influenza vaccine, in adults 18-64 years of age
- Illeszkedési kérdések
- Forrás: 2026-526925-17-00: ki vehet részt
- A regiszteradat frissítve
- 2026. október 6.